MARKETS LIVE: Wall Street dips as oil steadies

US PMI data exceeded expectations, with manufacturing and services PMIs at multi-year highs. Wall Street opened lower, with the Dow, S&P 500, and Nasdaq down. IonQ rose 5% after quantum error correction news, while General Mills fell 2% despite earnings beat. Meta's AI agent boosted shares, while biotechs like Viking Therapeutics and Celldex saw mixed movements. FTSE 100 closed flat, with Auto Trader Group leading losses.

Original reporting
Published Sep 23, 2026, 4:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 5:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MARKETS LIVE: Wall Street dips as oil steadies — source image
Decision brief

The 30-second read

$IONQBullishLow
01

Why it matters

Macro data and corporate catalysts together shape short‑term market direction; traders should weigh the relative weight of each.

02

Market read

US macro data and corporate news drive modest market pullback; sector impacts are nuanced.

03

What to watch

Potential policy shifts from the upcoming Trump‑Xi meeting could outweigh macro data in influencing risk sentiment.

Relevance 5/10Novelty 4/10Timing: pre‑market today

Background

The article provides a live market snapshot, reporting fresh US PMI numbers, oil price stability, and several company-specific moves.

Company-level read

Ticker impact

$IONQBullishMedium confidence
Context

IonQ jumped 5% after announcing a functional quantum error correction decoder, a fresh catalyst driving the move.

Expected impact

Potential further 2-3% gain in intraday trading.

Evidence & confidence

New technology announcement directly impacts valuation expectations.

$GISBearishMedium confidence
Context

General Mills fell 2% following its fiscal 2027 Q1 earnings release, which posted $0.75 EPS and $4.4B revenue.

Expected impact

Likely 1-2% further decline as investors reassess guidance.

Evidence & confidence

Earnings numbers were just released and moved the stock.

$VKTXBullishMedium confidence
Context

Viking Therapeutics rose 2% in pre‑market after obesity‑drug trial results sparked a 36% rally the previous day.

Expected impact

Expect continued 2‑3% upside if data holds.

Evidence & confidence

Recent trial success is a fresh catalyst for the biotech.

$CLDXBearishMedium confidence
Context

Celldex Therapeutics shares slipped after disappointing hives‑treatment trial results, extending a prior 12% slump.

Expected impact

Further 1‑2% decline likely in the short term.

Evidence & confidence

Trial disappointment is a new adverse catalyst.

Market effects

Stronger US PMI data supports industrials and financials, while oil price steadiness moderates energy sector volatility.

US equity indices dip modestly; UK FTSE shows mixed moves amid PMI and oil news.

Global markets watch US PMI and oil levels as early indicators for monetary policy and inflation trends.

Counterpoint

Despite positive PMI, the market may overreact to short‑term data, presenting buying opportunities on dips.

Key entities

  • IonQ

    Quantum computing firm reporting a breakthrough decoder.

  • General Mills

    Food producer reporting Q1 earnings.

  • Viking Therapeutics

    Biotech with positive obesity‑drug trial data.

  • Celldex Therapeutics

    Biotech facing trial disappointment.

Related articles

$IQMXMed

IonQ and Rigetti Take the Headlines, The Opportunity May Sit With Two Lesser-Known Quantum Stocks

IQM Quantum Computers (IQMX) and Quantinuum (QNT) are two lesser-known quantum computing companies gaining traction. IQMX sells and installs quantum computers, with a backlog of 102 million euros. QNT achieved a significant technical milestone with its Helios computer, reaching 99.9995% logical fidelity. Both companies have partnerships and are advancing commercialization, but neither is profitable yet.

$VKTXLowAI 8/10

Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2

Viking Therapeutics (VKTX) has initiated two Phase 3 trials for its oral weight loss drug, VK2735, targeting obesity and type 2 diabetes. The move follows mixed Phase 2 results, with concerns about tolerability. The company aims to improve outcomes with a longer trial duration, reduced tablet size, and lower dosing. Phase 1 data showed good tolerability, but Phase 2 had a 20% discontinuation rate due to adverse events.